HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lasting remission of a Muckle-Wells syndrome with CIAS-1 mutation using half-dose anakinra.

AuthorsStéphanie Gerard, Benoît le Goff, Yves Maugars, Jean-Marie Berthelot, Olivier Malard
JournalJoint bone spine (Joint Bone Spine) Vol. 74 Issue 6 Pg. 659 (Dec 2007) ISSN: 1778-7254 [Electronic] France
PMID17892965 (Publication Type: Case Reports, Letter)
Chemical References
  • Antirheumatic Agents
  • Carrier Proteins
  • Interleukin 1 Receptor Antagonist Protein
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • NLRP3 protein, human
Topics
  • Antirheumatic Agents (therapeutic use)
  • Carrier Proteins (genetics, metabolism)
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Hearing Loss, Sensorineural
  • Humans
  • Inflammation (drug therapy, genetics, metabolism)
  • Interleukin 1 Receptor Antagonist Protein (therapeutic use)
  • Male
  • Middle Aged
  • Mutation
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Pain (drug therapy)
  • Pain Measurement
  • Remission Induction
  • Syndrome
  • Treatment Outcome
  • Urticaria (drug therapy, genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: